NeutraControl IL-17A Monoclonal antibody
NeutraControl IL-17A Monoclonal Antibody for ELISA, Non-Neutralization
Host / Isotype
Mouse / IgG1
Reactivity
Human
Applications
ELISA, Non-Neutralization
Conjugate
Unconjugated
CloneNo.
2A7E2
Cat no : 69521-1-Ig
Synonyms
Validation Data Gallery
Product Information
69521-1-Ig targets IL-17A in ELISA, Non-Neutralization applications and shows reactivity with Human samples.
Tested Reactivity | Human |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Immunogen | human Humankine IL-17A protein HZ-1113 |
Full Name | interleukin 17A |
Gene Symbol | IL-17A |
Gene ID (NCBI) | 3605 |
RRID | AB_2918855 |
Conjugate | Unconjugated |
Form | Lyophilized Powder |
Purification Method | Protein G purification |
Storage Buffer | Sterile PBS. |
Endotoxin | <0.1 EU/μg |
Reconstitution | This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use. |
Stability and Storage | Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products. |
Background Information
IL17A, also named as IL-17, is a proinflammatory cytokine. IL-17, synthesized only by memory T cells and natural killer cells, has pleiotropic effects, mainly in the recruitment and activation of neutrophils. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The IL-17 receptor is a type I transmembrane protein, that is widely expressed on epithelial cells, fibroblasts, B and T cells, and monocytic cells. In psoriatic skin lesions, both Th17 cells and their downstream effector molecules, e.g. IL-17 and IL-22, are highly increased.
This antibody is a neutralizing control antibody for IL-17A, the immunogen is the same as Neutrakine 69021-1-Ig but could not neutralize human IL-17A.